Clinical significance of securin expression in solid cancers: A PRISMA-compliant meta-analysis of published studies and bioinformatics analysis based on TCGA dataset.

Szczegóły
Abstrakt

Tytuł:: Clinical significance of securin expression in solid cancers: A PRISMA-compliant meta-analysis of published studies and bioinformatics analysis based on TCGA dataset.
Autorzy:: Liu X; Department of Cardiothoracic Surgery, the Second Affiliated Hospital, University of South China, Hengyang, China.
Zeng W; Department of Cardiothoracic Surgery, the Second Affiliated Hospital, University of South China, Hengyang, China.
Zheng D; Department of Cardiothoracic Surgery, the Second Affiliated Hospital, University of South China, Hengyang, China.
Tang M; Department of Cardiothoracic Surgery, the Second Affiliated Hospital, University of South China, Hengyang, China.
Zhou W; Department of Medical Humanities and Education Department, the First Affiliated Hospital, University of South China, Hengyang, China.
Źródło:: Medicine [Medicine (Baltimore)] 2022 Sep 16; Vol. 101 (37), pp. e30440.
Typ publikacji:: Journal Article; Meta-Analysis
Język:: English
Imprint Name(s):: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
MeSH Terms:: Biomarkers, Tumor*/genetics
Biomarkers, Tumor*/metabolism
Computational Biology*
Humans ; Lymphatic Metastasis ; Prognosis ; Securin/genetics
References:: Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11:433–41.
Ito T, Shimada Y, Kan T, et al. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res. 2008;68:3214–24.
Parte S, Virant-Klun I, Patankar M, et al. PTTG1: a unique regulator of stem/cancer stem cells in the ovary and ovarian cancer. Stem cell Rev Rep. 2019;15:866–79.
Thomas C, Wetherall B, Levasseur MD, et al. A prometaphase mechanism of securin destruction is essential for meiotic progression in mouse oocytes. Nat Commun. 2021;12:4322.
Moreno-Mateos MA, Espina ÁG, Torres B, et al. PTTG1/securin modulates microtubule nucleation and cell migration. Mol Biol Cell. 2011;22:4302–11.
Romero F, Multon MC, Ramos-Morales F, et al. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 2001;29:1300–7.
Ogbagabriel S, Fernando M, Waldman FM, et al. Securin is overexpressed in breast cancer. Modern Pathol. 2005;18:985–90.
Karra H, Pitkänen R, Nykänen M, et al. Securin predicts aneuploidy and survival in breast cancer. Histopathology. 2012;60:586–96.
Li WH, Chang L, Xia YX, et al. Knockdown of PTTG1 inhibits the growth and invasion of lung adenocarcinoma cells through regulation of TGFB1/SMAD3 signaling. Int J Immunopathol Pharmacol. 2015;28:45–52.
Hu ZG, Zheng CW, Su HZ, et al. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma. J Cell Biochem. 2019;120:9964–78.
Yan S, Zhou C, Lou X, et al. PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res. 2009;69:3283–90.
Feng W, Xiaoyan X, Shenglei L, et al. PTTG1 cooperated with GLI1 leads to epithelial-mesenchymal transition in esophageal squamous cell cancer. Oncotarget. 2017;8:92388–400.
Cho-Rok J, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology (Baltimore, Md). 2006;43:1042–52.
Liang M, Liu J, Ji H, et al. A Aconitum coreanum polysaccharide fraction induces apoptosis of hepatocellular carcinoma (HCC) cells via pituitary tumor transforming gene 1 (PTTG1)-mediated suppression of the P13K/Akt and activation of p38 MAPK signaling pathway and displays antitumor activity in vivo. Tum Biol. 2015;36:7085–91.
Lin X, Yang Y, Guo Y, et al. PTTG1 is involved in TNF-α-related hepatocellular carcinoma via the induction of c-myc. Cancer Med. 2019;8:5702–15.
Kim DS, Franklyn JA, Smith VE, et al. Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis. 2007;28:749–59.
Fujii T, Nomoto S, Koshikawa K, et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology (Baltimore, Md). 2006;43:1267–75.
Su MC, Hsu HC, Liu YJ, et al. Overexpression of pituitary tumor-transforming gene-1 in hepatocellular carcinoma. Hepato-Gastroenterology. 2006;53:262–5.
Feng ZZ, Chen JW, Yang ZR, et al. Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression. Med Oncol. 2012;29:304–10.
Kim JW, Song JY, Lee JM, et al. Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker. Int J Gynecol Cancer. 2008;18:1352–9.
Genkai N, Homma J, Sano M, et al. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep. 2006;15:1569–74.
Xu MD, Dong L, Qi P, et al. Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer. Gastric Cancer. 2016;19:107–15.
Ma K, Ma L, Jian Z. Pituitary tumor-transforming 1 expression in laryngeal cancer and its association with prognosis. Oncol Letters. 2018;16:1107–14.
Ma K, Sun X, Ma L, et al. Expression of serum PTTG1 in laryngeal carcinoma and its correlation to prognosis. Clin Exp Otorhinolaryngol. 2020;13:64–8.
Li H, Yin C, Zhang B, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013;34:2145–55.
Ren Q, Jin B. The clinical value and biological function of PTTG1 in colorectal cancer. Biomed Pharmacothe. 2017;89:108–15.
Wei C, Yang X, Xi J, et al. High expression of pituitary tumor-transforming gene-1 predicts poor prognosis in clear cell renal cell carcinoma. Mol Clin Oncol. 2015;3:387–91.
Xiang W, Wu X, Huang C, et al. PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth. Oncotarget. 2017;8:664–78.
Li J, Wang P, Zhou Y, et al. A novel classification method of lymph node metastasis in colorectal cancer. Bioengineered. 2021;12:2007–21.
Liu R, Kong W, Deng M, et al. Association between hepatitis B virus infection and colorectal liver metastasis: a meta-analysis. Bioengineered. 2021;12:736–44.
Min SH, Zheng QQ. Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Medicine. 2021;100:e27919.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
Chen K, Gan JX, Huang ZP, et al. Clinical significance of long noncoding RNA MNX1-AS1 in human cancers: a meta-analysis of cohort studies and bioinformatics analysis based on TCGA datasets. Bioengineered. 2021;12:875–85.
Hu Y, Zhang Y, Gao J, et al. The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data. Bioengineered. 2020;11:572–81.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
Wang F, Liu Y, Chen Y. Pituitary tumor transforming gene-1 in non-small cell lung cancer: clinicopathological and immunohistochemical analysis. Biomed Pharmacother. 2016;84:1595–600.
Shibata Y, Haruki N, Kuwabara Y, et al. Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol. 2002;32:233–7.
Zhang J, Yang Y, Chen L, et al. Overexpression of pituitary tumor transforming gene (PTTG) is associated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Acta Histochem. 2014;116:435–9.
Zhang T, Li H, Zhang Y, et al. Expression of proteins associated with epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Oncol Letters. 2018;15:3042–8.
Rehfeld N, Geddert H, Atamna A, et al. The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinogen. 2006;5:4.
Sáez C, Martínez-Brocca MA, Castilla C, et al. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab. 2006;91:1404–9.
Heikkinen I, Almangush A, Hagström J, et al. Does securin expression have significance in prognostication of oral tongue cancer? A pilot study. Eur Arch Oto-Rhino-Laryngol. 2016;273:3905–11.
Chen Y, Yang JS, Deng L. Clinical significance of PTTG1 in sophageal squamous cell carcinoma. China J Mod Med. 2019;29:29–5.
Feng P, Li FG, Wang H, et al. Expression and clinical significance of pituitary tumor-transforming gene 1 in gastric carcinoma. Chin J Exp Surg. 2016;33:1342–4.
Wen FS, Li HL, Yin CG. Expression of pituitary tumor transforming gene 1, matrix metalloproteinase·2 and matrix metalloproteinase-9 in gastric carcinoma. World Chin J Digestol. 2015;23:3147–51.
Wu DL, Ma C, Xu HB, et al. Expression of pituitary transforming gene 1 in osteosarcoma tissues and its association with prognosis. Chongqing Med. 2016;45:3366–8.
Zeng GC, Mu JH, Li W. Correlation analysis of PTTG1 protein expression with the clinical features and prognosis of osteosarcoma. Anti Tum Pharm. 2017;7:493–8.
Zhao YL. Expression of PTTG1 and CyclinB1 in human colon carcinoma and its clinical significance. J Fourth Milit Med Univ. 2009;30:943–5.
Castilla C, Flores ML, Medina R, et al. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1. Mol Cancer Ther. 2014;13:2372–83.
Huang S, Liao Q, Li L, et al. PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation. Tum Biol. 2014;35:6265–70.
Huang S, Liao Q, Li W, et al. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1. Bull Cancer. 2021;108:359–68.
Huang SQ, Liao QJ, Wang XW, et al. RNAi-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells. Brazil J Med Biol Res. 2012;45:995–1001.
Zhang Z, Jin B, Jin Y, et al. PTTG1, A novel androgen responsive gene is required for androgen-induced prostate cancer cell growth and invasion. Exp Cell Res. 2017;350:1–8.
Zhu X, Mao Z, Na Y, et al. Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res. 2006;26:1253–9.
Chen Z, Cao K, Hou Y, et al. PTTG1 knockdown enhances radiation-induced antitumour immunity in lung adenocarcinoma. Life Sci. 2021;277:119594.
Chao JI, Liu HF. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol Pharmacol. 2006;69:154–64.
Kakar SS, Malik MT. Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol. 2006;29:387–95.
Qiu M, Li G, Wang P, et al. aarF domain containing kinase 5 gene promotes invasion and migration of lung cancer cells through ADCK5-SOX9-PTTG1 pathway. Exp Cell Res. 2020;392:112002.
Shah PP, Fong MY, Kakar SS. PTTG induces EMT through integrin αVβ3-focal adhesion kinase signaling in lung cancer cells. Oncogene. 2012;31:3124–35.
Wang W, Cao R, Su W, et al. miR-655-3p inhibits cell migration and invasion by targeting pituitary tumor-transforming 1 in non-small cell lung cancer. Biosci Biotechnol Biochem. 2019;83:1703–8.
Yu SY, Liu HF, Wang SP, et al. Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013;203:412–22.
Bernal JA, Luna R, Espina A, et al. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet. 2002;32:306–11.
Deng P, Tan M, Zhou W, et al. Bisphenol A promotes breast cancer cell proliferation by driving miR-381-3p-PTTG1-dependent cell cycle progression. Chemosphere. 2021;268:129221.
Ghayad SE, Vendrell JA, Bieche I, et al. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol. 2009;42:87–103.
Meng C, Zou Y, Hong W, et al. Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression. Mol Med (Cambridge, Mass). 2020;26:33.
Xiea Y, Wangb R. Pttg1 promotes growth of breast cancer through P27 nuclear exclusion. Cell Physiol Biochem. 2016;38:393–400.
Hamid T, Kakar SS. PTTG/securin activates expression of p53 and modulates its function. Mol Cancer. 2004;3:18.
Yoon CH, Kim MJ, Lee H, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem. 2012;287:19516–27.
Yan H, Wang W, Dou C, et al. Securin promotes migration and invasion via matrix metalloproteinases in glioma cells. Oncol Letters. 2015;9:2895–901.
Cui L, Ren T, Zhao H, et al. Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells. Med Oncol. 2020;37:73.
Su X, Chen J, Ni L, et al. Inhibition of PTTG1 expression by microRNA suppresses proliferation and induces apoptosis of malignant glioma cells. Oncol Letters. 2016;12:3463–71.
Zhi T, Jiang K, Xu X, et al. ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1. Neuro Oncol. 2019;21:462–73.
Zou Y, Qiu G, Jiang L, et al. Overexpression of ubiquitin specific proteases 44 promotes the malignancy of glioma by stabilizing tumor-promoter securin. Oncotarget. 2017;8:58231–46.
Hong H, Jin Z, Qian T, et al. Falcarindiol enhances cisplatin chemosensitivity of hepatocellular carcinoma via down-regulating the STAT3-modulated PTTG1 pathway. Front Pharmacol. 2021;12:656697.
Huang JL, Cao SW, Ou QS, et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer. 2018;17:93.
Yu SH, Yang PM, Peng CW, et al. Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis. Cancer Lett. 2011;300:96–104.
Tong Y, Zhao W, Zhou C, et al. PTTG1 attenuates drug-induced cellular senescence. PLoS One. 2011;6:e23754.
Wang X, Duan W, Li X, et al. PTTG regulates the metabolic switch of ovarian cancer cells via the c-myc pathway. Oncotarget. 2015;6:40959–69.
Wu D, Xia Y, Xu H, et al. [Impact of PTTG1 downregulation on cell proliferation, cell cycle and cell invasion of osteosarcoma and related molecular mechanisms]. Zhonghua bing li xue za zhi. 2014;43:695–8.
Teveroni E, Di Nicuolo F, Bianchetti G, et al. Nuclear localization of PTTG1 promotes migration and invasion of seminoma tumor through activation of MMP-2. Cancers. 2021;13:212.
Read ML, Modasia B, Fletcher A, et al. PTTG and PBF functionally interact with p53 and predict overall survival in head and neck cancer. Cancer Res. 2018;78:5863–76.
Liu X, Cai Y, Cheng C, et al. PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis. Cell Death Dis. 2022;13:178.
Zhang E, Liu S, Xu Z, et al. Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial-mesenchymal transition (EMT) in SCC15 cells. Tum Biol. 2014;35:8801–11.
Guo XC, Li L, Gao ZH, et al. The long non-coding RNA PTTG3P promotes growth and metastasis of cervical cancer through PTTG1. Aging. 2019;11:1333–41.
Solbach C, Roller M, Peters S, et al. Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy. Anticancer Res. 2005;25:121–5.
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (Securin)
Entry Date(s):: Date Created: 20220920 Date Completed: 20220922 Latest Revision: 20221108
Update Code:: 20240105
PubMed Central ID:: PMC9478268
DOI:: 10.1097/MD.0000000000030440
PMID:: 36123907
: Czasopismo naukowe

Full Text Finder

Background: Numerous studies have investigated the clinical significance of securin expression in solid cancers; however, the results have been inconsistent. Hence, we performed a meta-analysis of published studies to assess the clinical value of securin expression in patients with solid cancers.
Methods: The Chinese National Knowledge Infrastructure, Web of Science, PubMed, and EMDASE databases were searched for eligible studies (from inception up to April 2021). Bioinformatics analysis based on The Cancer Genome Atlas dataset was also performed to evaluate the prognostic value of securin expression.
Results: A total of 25 articles with 26 studies were included in the meta-analysis. The results of the meta-analysis implied that high securin expression was positively correlated with unfavorable overall survival (OS) (hazard ratio = 1.52, 95% CI, 1.33-1.73; P < .001) and lymph node metastasis (odd ratio = 2.96, 95% CI, 2.26-3.86; P < .001). Consistently, our bioinformatics analysis showed that increased securin expression was associated with worse OS and shorter disease-free survival in cancer patients.
Conclusion: Our study indicated that securin overexpression was positively associated with metastasis and inversely related to the prognosis of patients with solid cancers. However, additional high-quality studies should be conducted to validate these findings.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)

Informacja